Disturbed apolipoprotein A-I-containing lipoproteins in fish-eye disease are improved by the lecithin:cholesterol acyltransferase produced by gene-transduced adipocytes in vitro

Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness

“…In future studies, it would be of interest to examine whether treatment specifically aimed at increasing HDL-c will affect arterial stiffness. Also, our data bolster the notion that LCAT might be an interesting target to reduce cardiovascular risk and support LCAT enhancing strategies currently evaluated in preclinical studies [28,29]. …”

HDL-cholesterol and cardiovascular disease

“…A small molecule activator of LCAT resulted in increased HDL-C and decreased triglycerides in mice and hamsters [56]. Recombinant LCAT improves HDL-C levels in LCAT-deficient mice [57], and gene-transduced adipocytes were capable of raising HDL-C levels in LCAT deficiency [58]. LCAT replacement therapy is a logical approach to reducing the risk of chronic kidney disease in LCAT deficiency.…”

Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?

“…The mice had marked increases in HDL cholesterol and particle size, whereas LDL cholesterol, plasma triglycerides, and plasma apoB were reduced. Kuroda and colleagues have focused on developing a long-lasting LCAT replacement therapy via transplantation of human LCAT gene-transduced autologous adipocytes ( 142,143 ). LCAT from the transduced adipocytes improved the abnormal HDL particles from an FED patient in vitro ( 142 ).…”

“…Kuroda and colleagues have focused on developing a long-lasting LCAT replacement therapy via transplantation of human LCAT gene-transduced autologous adipocytes ( 142,143 ). LCAT from the transduced adipocytes improved the abnormal HDL particles from an FED patient in vitro ( 142 ). Furthermore, LCAT could be steadily detected in adipocyte transplanted mice at four weeks after transplantation ( 129 ).…”